Faron Pharmaceuticals Ltd | Company announcement | June 03, 2026 at 14:00:00 EEST
Capitalised terms used in this announcement have the meanings given to them in the announcement made on 3 June 2026 at 09:00 EEST regarding the amortisation payment and approval of share subscriptions based on special rights, unless the context provides otherwise.
Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, has, as announced today on 3 June 2026, approved the exercise of 3,366,377 Special Rights entitling to 3,366,377 new Shares, for an aggregate subscription price of EUR 1,596,000.
In total, 3,366,377 new Shares in the Company have today on 3 June 2026 been registered in the Finnish Trade Register. The Shares rank pari passu in all respects with the existing shares of the Company. Following the registration of new Shares, the aggregate number of ordinary shares in the Company is 206,411,888 and of these shares, the Company holds 3,530,573 shares in treasury. The shares held in treasury by the Company do not confer a right to dividends or other shareholder rights. The Company announced on 28 May 2026 that it had issued 21,469,427 treasury shares to the Company itself and expects these shares to be registered on or around 10 June 2026. Once these shares are registered, the total number of shares in the Company will be 227,881,315, of which the Company then holds 25,000,000 shares in treasury.
Trading in the new Shares is expected to commence on First North and AIM on or around 4 June 2026.
For more information, please contact:
| IR Partners, Finland (Media) Kare Laukkanen | +358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi |
| FINN Partners, US (Media) Alyssa Paldo | +1 847 791-8085 alyssa.paldo@finnpartners.com |
| Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner | +44 (0) 207 213 0880 |
| Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä | +358 (0)40 555 4727 +358 (0)50 553 8990 |
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.